Farmak International at ECR 2025: Expanding Global Access to Essential Pharmaceutical Solutions in Radiology
Farmak International, a global pharmaceutical company with a strong presence in contrast media, complex generics, and anesthesiology and intensive care products, is proud to participate in ECR 2025.
As radiology continues to advance with AI, digital imaging, and data-driven diagnostics, the need for high-quality contrast media remains as critical as ever.
Farmak International’s contrast agents are trusted in over 60 countries, ensuring radiologists worldwide have consistent access to reliable imaging solutions. With recent regulatory approval in China for our MRI contrast agent (read more here), we continue to expand access to high-quality diagnostic solutions across Europe, MEA, and Asia.
High-Quality Contrast Media: A Cornerstone of Evolving Radiology
At ECR 2025, Farmak International is highlighting its expanding portfolio of contrast media solutions for MRI and X-ray imaging, trusted by healthcare providers across Europe, the Middle East, Asia, and beyond. Its MRI contrast agents include gadolinium-based formulations designed to enhance soft tissue visualization, while its X-ray contrast media, based on iodinated compounds, support critical diagnostic procedures such as cardiovascular, neurological, and gastrointestinal imaging. These solutions align with Farmak International’s commitment to driving quality medicines worldwide, ensuring precision and reliability in medical diagnostics.
At ECR 2025, our team is engaging with healthcare professionals, distributors, and industry partners to further our mission of “Driving Quality Medicines Worldwide.” This event also provides an opportunity for Farmak Group’s international teams to connect, exchange insights, and strengthen collaborations in radiology and beyond.
Explore Farmak International’s portfolio of contrast media and other pharmaceutical solutions.
